RFRowan Frunt

Rowan Frunt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rowan Frunt has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Plasmin-mediated cleavage of GPIbα contributes to breakdown of platelet-von Willebrand factor complexes

    by Rowan Frunt, Elfie I. Moesker, Kazuya Sakai, Masanori Matsumoto, Albert Huisman, Claudia Tersteeg, Hinde El Otmani

    Von Willebrand factor (VWF) is an essential contributor to hemostasis through its interaction with the platelet glycoprotein (GP) Ibα receptor. VWF is cleaved by ADAMTS13 to limit its prothrombotic properties. Failure to do so can result in platelet-VWF complexes that occlude the microcirculation, as seen in thrombotic thrombocytopenic purpura (TTP). In this setting, plasmin becomes active to cleave VWF, forming a distinct plasmin-generated cleavage product of VWF (cVWF) that is detectable during acute attacks in patients with TTP and following therapeutic plasminogen activation in a mouse model of TTP. However, it remains unclear whether plasmin-mediated proteolysis of VWF alone accounts for the breakdown of platelet-VWF complexes. Using ristocetin-induced platelet agglutinations, we show that plasmin cleavage of VWF does not impair its platelet-binding capacity, whereas plasmin-mediated cleavage of GPIbα reduces the ability of platelets released from agglutinates to bind VWF. Furthermore, platelets in suspension are relatively resistant to plasmin cleavage. We therefore propose that VWF binding may enhance GPIbα cleavage by recruiting plasmin(ogen) to the platelet surface. In a TTP mouse model, plasminogen activation led to a VWF-dependent reduction in GPIbα detectability, although to a lesser extent than observed in vitro. In patients with acute TTP, soluble GPIbα levels were elevated, indicating increased GPIbα shedding during attacks of thrombotic microangiopathy, although the extent to which this is plasmin-mediated remains unclear. Together, our findings demonstrate that plasmin cleavage of GPIbα drives the disruption of ristocetin-induced agglutinates, while its contribution to the breakdown of platelet-VWF complexes in vivo appears limited.

  • Open Access

    Serum heat inactivation diminishes ApoE-mediated uptake of D-Lin-MC3-DMA lipid nanoparticles

    by Demian van Straten, Luuk van de Schepop, Rowan Frunt, Pieter Vader, Raymond M. Schiffelers

    Nanoparticles play a crucial role in drug delivery research. The protein corona that develops on the surface of nanoparticles after administration has garnered substantial attention due to the significant effects it has on their performance. Lipid nanoparticles (LNPs) depend on protein corona formation to mediate their targeting. Such protein–nanoparticle interactions are often initially studied using in vitro cellular models aiming to eventually understand biodistribution and cargo delivery efficiency of the LNPs in vivo. For in vitro cell culture, fetal calf serum (FCS) is supplemented to culture media to provide nutrients and promote cell viability and growth. Heat inactivation of FCS is often performed to prevent complement system activation. However, the effect of this process on protein corona formation and, in turn, LNP functionality is unclear. Here, we investigated the effects of serum heat inactivation on protein corona formation on LNPs containing D-lin-MC3-DMA (MC3) or C12-200 (C12) ionizable lipids. Cellular uptake and siRNA delivery efficiency of the LNPs were determined in media containing untreated or heat-inactivated serum. Mechanistically, we found that apolipoprotein E, a protein corona component that is crucial for MC3 LNP tropism, displayed reduced stability and functionality upon heat inactivation of FCS, thereby negatively influencing uptake and cargo delivery of MC3 LNPs, but not C12 LNPs. Our results underline the importance of overlooked factors in in vitro experiments that can inadvertently affect LNP performance. These findings can help to improve protocols to study protein corona formation in vitro and prevent bias in LNP development.


  • Open Access

    EV‐Elute: A universal platform for the enrichment of functional surface marker‐defined extracellular vesicle subpopulations

    by Willemijn S. de Voogt, Rowan Frunt, Raul M. Leandro, Casper S. Triesscheijn, Bella Monica, Ioanna Paspali, Mark Tielemans, Jerney J. J. M. François, Cor W. Seinen, Olivier G. de Jong, et al.

    Intercellular communication via extracellular vesicles (EVs) has been identified as a vital component of a steadily expanding number of physiological and pathological processes. To accommodate these roles, EVs have highly heterogeneous molecular compositions. Given that surface molecules on EVs determine their interactions with their environment, EV functionality likely differs between subpopulations with varying surface compositions. However, it has been technically challenging to examine such functional heterogeneity due to a lack of non‐destructive methods to separate EV subpopulations based on their surface markers. Here, we used the Design‐of‐Experiments (DoE) methodology to optimize a protocol, which we name ‘EV‐Elute’, to elute intact EVs from commercially available Protein G‐coated magnetic beads. We captured EVs from various cell types on these beads using antibodies against CD9, CD63, CD81 and a custom‐made protein binding phosphatidylserine (PS). When applying EV‐Elute, over 70% of bound EVs could be recovered from the beads in a pH‐ and incubation‐time‐dependent fashion. EV subpopulations showed intact integrity by electron microscopy and Proteinase K protection assays and showed uptake patterns similar to whole EV isolates in co‐cultures of peripheral blood mononuclear cells (PBMCs) and endothelial cells. However, in Cas9/sgRNA delivery assays, CD63+ EVs showed a lower capacity to functionally deliver cargo as compared to CD9+, CD81+ and PS+ EVs. Taken together, we developed a novel, easy‐to‐use platform to isolate and functionally compare surface marker‐defined EV subpopulations. This platform does not require specialized equipment or reagents and is universally applicable to any capturing antibody and EV source. Hence, EV‐Elute can open new opportunities to study EV functionality at the subpopulation level.


  • Open Access

    Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis

    by Hinde El Otmani, Rowan Frunt, Simone Smits, Arjan D. Barendrecht, Steven de Maat, Rob Fijnheer, Peter J. Lenting, Claudia Tersteeg

    Von Willebrand factor (VWF) is an essential contributor to microvascular thrombosis. Physiological cleavage by ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) limits its prothrombotic properties, explaining why ADAMTS13 deficiency leads to attacks of microthrombosis in patients with thrombotic thrombocytopenic purpura (TTP). We previously reported that plasminogen activation takes place during TTP attacks in these patients. Furthermore, stimulation of plasminogen activation attenuates pathogenesis in preclinical TTP models in vivo. This suggests that plasmin is an endogenous regulator of VWF thrombogenicity, in particular when ADAMTS13 falls short to prevent microvascular occlusions. VWF cleavage by plasmin is biochemically distinct from cleavage by ADAMTS13. We hypothesized that plasmin-cleaved VWF (cVWF) holds value as a biomarker of microvascular thrombosis. Here, we describe the development of a variable domain of heavy-chain-only antibody (VHH)-based bioassay that can distinguish cVWF from intact and ADAMTS13-cleaved VWF in plasma. We validate this assay by tracking cVWF release during degradation of microthombi in vitro. We demonstrate that endogenous cVWF formation takes place in patients with TTP during acute attacks of thrombotic microangiopathy but not in those in remission. Finally, we show that therapeutic plasminogen activation in a mouse model of TTP amplifies cVWF formation, which is accompanied by VWF clearance. Our combined findings indicate that cVWF is released from microthrombi in the context of microvascular occlusion.


  • Open Access

    Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis

    by Niels van Nieuwenhuijzen, Rowan Frunt, Anne M. May, Monique C. Minnema

    Great progress in the treatment of patients with multiple myeloma (MM) has been made due to the development of novel drugs. Patients with relapsed/refractory MM (RRMM) can be enrolled in early-phase clinical trials, but their performance across the last decade is unknown. We conducted a meta-analysis on the overall response rate (ORR) and toxicity. PubMed, Embase, and Cochrane Library were systematically searched for phase I and phase II trials investigating an experimental compound as a single agent or in combination with dexamethasone, published from January 1, 2010 to July 1, 2020. Eighty-eight articles were included, describing 61 phase I trials involving 1835 patients and 37 phase II trials involving 2644 patients. There was a high degree of heterogeneity. Using a random-effects model, the 95% CIs of the estimated ORR were 8–17% for phase I trials and 18–28% for phase II trials. There were significant subgroup differences in ORR between the years of publication in phase I trials and between drug classes in both phase I and phase II trials. The ORR in early-phase clinical trials in RRMM is substantial, especially in phase II trials, but due to high heterogeneity a general assessment of clinical benefit before participation is difficult to offer to patients.